Benztropine Mesylate 1 mg Tablet, 1,000-count — NDC 50228-226-10 (Billing 50228-0226-10)
This is a package of 1,000 tablets of Benztropine Mesylate 1 mg Tablet from ScieGen Pharmaceuticals Inc, marketed since Nov 2024 and currently FDA-listed; retail pharmacies pay about $0.0753 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 50228-226-10 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 50228 labeler · 226 product · 10 package
- Package marketed since
- Nov 5, 2024
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Billing quantity
- 1,000 EA per package
- Barcode (UPC-A, from the NDC)
- 3 5022822610 3
- Medicaid fills, this package
- 80,864 prescriptions in the last four reported quarters
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 004590
- GCN: 17621
- GPI-14 (Medi-Span): 73100010100310
- HICL (First Databank): 001905
- AHFS class code: 12:08.04.00
- RxCUI (RxNorm): 885209
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
RxNorm drug class
This medicine belongs to the Anticholinergic class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Benztropine is used along with other medications to treat the symptoms of Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance) and tremors caused by other medical problems or medications. Benztropine is in a class of medications called anticholinergics. It works by blocking a certain natural substance (acetylcholine) to help to decrease symptoms in people with Parkinson's disease.
Read the full MedlinePlus article ↗- It's used alongside other treatments for parkinsonism, which means Parkinson's-type movement problems. It also helps control movement side effects caused by drugs like phenothiazin...
- Tablets are taken by mouth, and some people take the whole dose at bedtime while others split it through the day. Your prescriber will start you low and raise it slowly. Follow you...
- Dry mouth, constipation, nausea, blurred vision, and trouble urinating are common. Call us if dry mouth makes swallowing or speaking hard. Tell your doctor about a rash too.
- Yes, overheating. Benztropine can reduce sweating, so be careful in hot weather. Call your doctor for fever, heat intolerance, stomach or bowel problems, confusion, or hallucinatio...
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.075 | $75.30 / 1000 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.2160 | $216.00 / 1000 tablets |
| Medicare drug plans payPart D · Q2 2026 | $0.1636 | $163.60 / 1000 tablets |
Where does this data come from?
- CMS NADAC weekly file · file of Oct 7, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 50228-0226-01 50228-226-01 | 100 TABLET in 1 BOTTLE | $0.0753 / ea | $7.53 | 2024-11-05 | — | Active |
| 50228-0226-10 You're viewing this Main listing | 1000 TABLET in 1 BOTTLE | $0.0753 / ea | $75.30 | 2024-11-05 | — | Active |
You're viewing the largest of 2 pack sizes for this product.
This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.0753 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 62% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 50228-0226-01?
What NDC number is used to bill for this package of Benztropine Mesylate 1 mg Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Benztropine Mesylate 1 mg 00904-7289-61 | Major | 100 tablets | $0.075 | AA | Availability likely | — |
| Benztropine Mesylate 1 mg 11534-0168-09 | SUNRISE | 100 tablets | $0.075 | AA | Availability likely | — |
| Benztropine Mesylate 1 mgthis 50228-0226-10 | ScieGen | 1000 tablets | $0.075 | AA | Availability likely | — |
| Benztropine Mesylate 1 mg 62135-0144-01 | Chartwell | 100 tablets | $0.075 | AA | Availability likely | — |
| Benztropine Mesylate 1 mg 68084-0388-01 | American | 100 tablets | $0.075 | AA | Availability likely | — |
| Benztropine Mesylate 1 mg 69315-0137-01 | Leading | 100 tablets | $0.075 | AA | Availability likely | — |
| Benztropine Mesylate 1 mg 70752-0124-10 | QUAGEN | 100 tablets | $0.075 | AA | Availability likely | — |
| Benztropine Mesylate 1 mg 00603-2434-10 | Par | 10 tablets | — | AA | Discontinued | — |
| Benztropine Mesylate 1 mg 00615-8223-39 | NCS | 30 tablets | — | AA | Discontinued | — |
| Benztropine Mesylate 1 mg 10135-0814-01 | Marlex | 100 tablets | — | AA | FDA listed | — |
| Benztropine Mesylate 1 mg 50090-7017-00 | A-S | 100 tablets | — | AA | FDA listed | — |
| Benztropine Mesylate 1 mg 63187-0840-03 | Proficient | 3 tablets | — | AA | FDA listed | — |
| Benztropine Mesylate 1 mg 67046-0041-03 | Coupler | 30 tablets | — | AA | FDA listed | — |
| Benztropine Mesylate 1 mg 69097-0827-02 | Cipla | 30 tablets | — | — | FDA listed | — |
| Benztropine Mesylate 1 mg 70518-0132-01 | REMEDYREPACK | 30 tablets | — | — | FDA listed | — |
| Benztropine Mesylate 1 mg 70518-0577-00 | REMEDYREPACK | 30 tablets | — | AA | FDA listed | — |
| Benztropine Mesylate 1 mg 71610-0502-53 | Aphena | 60 tablets | — | AA | FDA listed | — |
| Benztropine Mesylate 1 mg 72162-2595-00 | Bryant | 1000 tablets | — | AA | FDA listed | — |
| Benztropine Mesylate 1 mg 87441-0012-01 | Unit | 30 tablets | — | AA | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Oct 7, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Oct 8, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Benztropine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 3SY5LH9PMK
Anhydrous lactose is a milk sugar with no water content. It acts as a filler and binder in tablets and capsules, adding bulk and helping ingredients stick together.
-
UNII M28OL1HH48
Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
-
UNII 6T47AS764T
Red 40 Lake is a synthetic colorant made by combining Red 40 dye with aluminum hydroxide. It's used to give tablets, capsules, and other medicines a red or pink color for identification and appearance.
-
UNII JQ6BLH9FR7
FD&C Yellow No. 5 Aluminum Lake is a bright yellow colorant made by combining a synthetic dye with aluminum and other salts. It colors tablets and capsules to help identify the medication and make it visually distinctive.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII FZ989GH94E
Povidone is a synthetic polymer made from a plastic-like material. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in your stomach so the medicine can be absorbed.
6 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 8, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from ScieGen Pharmaceuticals Inc labeler code 50228
- Lacosamide 100 mg Tablet, Film Coated NDC 50228-193-10
- Lacosamide 150 mg Tablet, Film Coated NDC 50228-194-10
- Lacosamide 200 mg Tablet, Film Coated NDC 50228-195-10
- fexofenadine hcl 60 mg Tablet, Film Coated NDC 50228-201-01
- fexofenadine hcl 180 mg Tablet, Film Coated NDC 50228-202-01
- Benztropine Mesylate .5 mg Tablet NDC 50228-225-01
- Benztropine Mesylate 2 mg Tablet NDC 50228-227-01
- Enalapril Maleate 2.5 mg Tablet NDC 50228-228-01
- Enalapril Maleate 5 mg Tablet NDC 50228-229-01
- Enalapril Maleate 10 mg Tablet NDC 50228-230-01
- Enalapril Maleate 20 mg Tablet NDC 50228-231-01
- Metoclopramide 5 mg Tablet NDC 50228-232-01
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines).
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Benztropine mesylate tablets should be used when patients are able to take oral medication. Because of cumulative action, therapy should be initiated with a low dose which is increased gradually at five- or six-day intervals to the smallest amount necessary for optimal relief. Increases should be made in increments of 0.5 mg, to a maximum of 6 mg, or until optimal results are obtained without excessive adverse reactions.
Postencephalitic and Idiopathic Parkinsonism - The usual daily dose is 1 to 2 mg, with a range of 0.5 to 6 mg orally. As with any agent used in parkinsonism, dosage must be individualized according to age and weight, and the type of parkinsonism being treated. Generally, older patients, and thin patients cannot tolerate large doses.
Most patients with postencephalitic parkinsonism need fairly large doses and tolerate them well. Patients with a poor mental outlook are usually poor candidates for therapy. In idiopathic parkinsonism, therapy may be initiated with a single daily dose of 0.5 to 1 mg at bedtime.
In some patients, this will be adequate; in others 4 to 6 mg a day may be required. In postencephalitic parkinsonism, therapy may be initiated in most patients with 2 mg a day in one or more doses. In highly sensitive patients, therapy may be initiated with 0.5 mg at bedtime, and increased as necessary.
Some patients experience greatest relief by taking the entire dose at bedtime; others react more favorably to divided doses, two to four times a day. Frequently, one dose a day is sufficient, and divided doses may be unnecessary or undesirable. The long duration of action of this drug makes it particularly suitable for bedtime medication when its effects may last throughout the night, enabling patients to turn in bed during the night more easily, and to rise in the morning.
When benztropine mesylate is started, do not terminate therapy with other antiparkinsonian agents abruptly. If the other agents are to be reduced or discontinued, it must be done gradually. Many patients obtain greatest relief with combination therapy.
Benztropine mesylate may be used concomitantly with Carbidopa-Levodopa, or with levodopa, in which case periodic dosage adjustment may be required in order to maintain optimum response. Drug-Induced Extrapyramidal Disorders - In treating extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), the recommended dosage is 1 to 4 mg once or twice a day orally. Dosage must be individualized according to the need of the patient.
Some patients require more than recommended; others do not need as much. When extrapyramidal disorders develop soon after initiation of treatment with neuroleptic drugs (e.g., phenothiazines), they are likely to be transient. One to 2 mg of benztropine mesylate tablets two or three times a day usually provides relief within one or two days.
After one or two weeks, the drug should be withdrawn to determine the continued need for it. If such disorders recur, benztropine mesylate can be reinstituted. Certain drug-induced extrapyramidal disorders that develop slowly may not respond to benztropine mesylate.
⛔ Contraindications ▾
CONTRAINDICATIONS Hypersensitivity to benztropine mesylate tablets. Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.
⚠️ Warnings ▾
WARNINGS Safe use in pregnancy has not been established. Benztropine mesylate may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly.
Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. Since benztropine mesylate contains structural features of atropine, it may produce anhidrosis. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment.
Anhidrosis may occur more readily when some disturbance of sweating already exists. If there is evidence of anhidrosis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired.
Severe anhidrosis and fatal hyperthermia have occurred.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The adverse reactions below, most of which are anticholinergic in nature, have been reported and within each category are listed in order of decreasing severity. Cardiovascular Tachycardia. Digestive Paralytic ileus, constipation, vomiting, nausea, dry mouth.
If dry mouth is so severe that there is difficulty in swallowing or speaking, or loss of appetite and weight, reduce dosage, or discontinue the drug temporarily. Slight reduction in dosage may control nausea and still give sufficient relief of symptoms. Vomiting may be controlled by temporary discontinuation, followed by resumption at a lower dosage.
Nervous System Toxic psychosis, including confusion, disorientation, memory impairment, visual hallucinations; exacerbation of pre-existing psychotic symptoms; nervousness; depression; listlessness; numbness of fingers. Special Senses Blurred vision, dilated pupils. Urogenital Urinary retention, dysuria.
Metabolic/Immune or Skin Occasionally, an allergic reaction, e.g., skin rash, develops. If this cannot be controlled by dosage reduction, the medication should be discontinued. Other Heat stroke, hyperthermia, fever.
🔄 Drug Interactions ▾
Drug Interactions Antipsychotic drugs such as phenothiazines or haloperidol; tricyclic antidepressants (see WARNINGS ).
🧒 Pediatric Use ▾
Pediatric Use Because of the atropine-like side effects, benztropine mesylate should be used with caution in pediatric patients over three years of age (see CONTRAINDICATIONS ).
🆘 Overdosage ▾
OVERDOSAGE Manifestations - May be any of those seen in atropine poisoning or antihistamine overdosage; CNS depression, preceded or followed by stimulation; confusion; nervousness; listlessness; intensification of mental symptoms or toxic psychosis in patients with mental illness being treated with neuroleptic drugs (e.g., phenothiazines); hallucinations (especially visual); dizziness; muscle weakness; ataxia; dry mouth; mydriasis; blurred vision; palpitations; tachycardia; elevated blood pressure; nausea; vomiting; dysuria; numbness of fingers; dysphagia; allergic reactions, e.g., skin rash; headache; hot, dry, flushed skin; delirium; coma; shock; convulsions; respiratory arrest; anhidrosis; hyperthermia; glaucoma; constipation.
Treatment - Physostigmine salicylate, 1 to 2 mg, SC or IV, reportedly will reverse symptoms of anticholinergic intoxication. * A second injection may be given after 2 hours if required. Otherwise treatment is symptomatic and supportive. Induce emesis or perform gastric lavage (contraindicated in precomatose, convulsive, or psychotic states).
Maintain respiration. A short-acting barbiturate may be used for CNS excitement, but with caution to avoid subsequent depression; supportive care for depression (avoid convulsant stimulants such as picrotoxin, pentylenetetrazol, or bemegride); artificial respiration for severe respiratory depression; a local miotic for mydriasis and cycloplegia; ice bags or other cold applications and alcohol sponges for hyperpyrexia, a vasopressor and fluids for circulatory collapse. Darken room for photophobia.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Benztropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. In the isolated guinea pig ileum, the anticholinergic activity of this drug is about equal to that of atropine; however, when administered orally to unanesthetized cats, it is only about half as active as atropine. In laboratory animals, its antihistaminic activity and duration of action approach those of pyrilamine maleate.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Benztropine Mesylate Tablets, USP are available as follows: 0.5 mg: White, biconvex, round tablets, debossed with “337” on one side, and plain with a bisect on the other side, in bottles of 100 (NDC 50228- 225-01), and 1,000 (NDC 50228-225-10). 1 mg: Light yellow, round, biconvex tablets debossed with “338” on one side and plain with a bisect on the other side, in bottles of 100 (NDC 50228-226-01) and 1,000 (NDC 50228-226-10). 2 mg: Light red, round, biconvex tablets debossed with “339” on one side and plain with a bisect on the other side, in bottles of 100 (NDC 50228-227-01) and 1,000 (NDC 50228-227-10).
Dispense in well-closed containers as defined in the USP. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep out of reach of children.
For more details please call 1-855-724-3436. Dispense the Prescribing Information at: https://sciegenpharm.com/medication-guide/ * Duvoisin, R.C.; Katz, R.J.; Amer. Med.
Ass. 206 : 1963–1965, Nov. 25, 1968.
Manufactured by: A&Z Pharmaceutical, Inc., 180 Oser Ave. Suite 300 Hauppauge, NY 11788 Manufactured for: ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788 Revised: 12/2025 LB8080
📋 Description ▾
DESCRIPTION Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine. It is designated chemically as 3α-(Diphenylmethoxy)-1αH, 5αH-tropane methanesulfonate. Its molecular formula is C 21 H 25 NO•CH 4 O 3 S, and its structural formula is: Benztropine mesylate is a crystalline white powder, very soluble in water, and has a molecular weight of 403.54.
Each benztropine mesylate tablet USP for oral administration contains benztropine mesylate USP 0.5 mg, 1 mg or 2 mg. Inactive ingredients: anhydrous lactose, croscarmellose sodium, FD&C Red #40 Aluminum Lake (2mg), FD&C Yellow #5 Aluminum Lake (1mg), povidone k-29/32, and magnesium stearate. Structure
⚠️ Precautions ▾
PRECAUTIONS General Since benztropine mesylate has cumulative action, continued supervision is advisable. Patients with a tendency to tachycardia and patients with prostatic hypertrophy should be observed closely during treatment. Dysuria may occur, but rarely becomes a problem.
Urinary retention has been reported with benztropine mesylate. The drug may cause complaints of weakness and inability to move particular muscle groups, especially in large doses. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern.
In this event, dosage adjustment is required. Mental confusion and excitement may occur with large doses, or in susceptible patients. Visual hallucinations have been reported occasionally.
Furthermore, in the treatment of extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), in patients with mental disorders, occasionally there may be intensification of mental symptoms. In such cases, antiparkinsonian drugs can precipitate a toxic psychosis. Patients with mental disorders should be kept under careful observation, especially at the beginning of treatment or if dosage is increased.
Tardive dyskinesia may appear in some patients on long-term therapy with phenothiazines and related agents, or may occur after therapy with these drugs has been discontinued. Antiparkinsonism agents do not alleviate the symptoms of tardive dyskinesia, and in some instances may aggravate them. Benztropine mesylate is not recommended for use in patients with tardive dyskinesia.
The physician should be aware of the possible occurrence of glaucoma. Although the drug does not appear to have any adverse effect on simple glaucoma, it probably should not be used in angle-closure glaucoma.
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL NDC 50228-225-01 Benztropine Mesylate Tablets, USP 0.5 mg 100 Tablets Rx Only ScieGen Pharmaceuticals Inc. PRINCIPAL DISPLAY PANEL NDC 50228-225-10 Benztropine Mesylate Tablets, USP 0.5 mg 1,000 Tablets Rx Only ScieGen Pharmaceuticals Inc. Benztropine Mesylate tab 0.5mg 100s label Benztropine Mesylate tab 0.5mg 1000s label
PRINCIPAL DISPLAY PANEL NDC 50228-226-01 Benztropine Mesylate Tablets, USP 1 mg 100 Tablets Rx Only ScieGen Pharmaceuticals Inc. PRINCIPAL DISPLAY PANEL NDC 50228-226-10 Benztropine Mesylate Tablets, USP 1 mg 1,000 Tablets Rx Only ScieGen Pharmaceuticals Inc. Benztropine Mesylate tab 1mg 100s label Benztropine Mesylate tab 1mg 1000s label
PRINCIPAL DISPLAY PANEL NDC 50228-227-01 Benztropine Mesylate Tablets, USP 2 mg 100 Tablets Rx Only ScieGen Pharmaceuticals Inc. PRINCIPAL DISPLAY PANEL NDC 50228-227-10 Benztropine Mesylate Tablets, USP 2 mg 1,000 Tablets Rx Only ScieGen Pharmaceuticals Inc. Benztropine Mesylate tab 2mg 100s label Benztropine Mesylate tab 2mg 1000s label